1 DNA Way Mailstop 258A
South San Francisco
About Genentech, Inc.
1470 articles with Genentech, Inc.
Imbio, a leading provider of artificial intelligence solutions for medical imaging analysis, has partnered with Genentech, a member of the Roche Group, to develop quantitative imaging diagnostics for lung diseases.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
"We are very excited to have entered into this transformative agreement that marks the start of a new era for Vaccibody,” Michael Engsig, CEO of Vaccibody, said in a statement.
Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants With Type 1 Spinal Muscular Atrophy (SMA)
Exploratory efficacy data showed 88% of infants treated with Evrysdi were alive and did not require permanent ventilation at two years
9/28/2020The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
The drug failed to meet its primary efficacy endpoint, as well as two secondary endpoints.
Genentech, a Roche company, presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer at the European Society for Medical Oncology Virtual Congress 2020 this weekend.
9/21/2020It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapy
85% of participants in the trial were from minority racial and ethnic groups, which are historically underrepresented in clinical studies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
9/14/2020It was a busy week for clinical trial updates. Here’s a look.
New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis
75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to Ocrevus in open-label Phase IIIb CASTING study
New Data Show Genentech’s Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum Disorder
Enspryng was recently approved by the U.S. Food and Drug Administration (FDA) for adults with anti-aquaporin-4 (AQP4) antibody positive NMOSD
The new data was on reducing relapse severity in NMOSD.
Genentech Expands Its Multiple Sclerosis Portfolio With Investigational BTK Inhibitor Fenebrutinib and Initiates Novel Clinical Trials for Ocrevus (ocrelizumab)
Phase III clinical trial program initiated for investigational medicine fenebrutinib, designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS)
Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
– Gavreto is a once-daily, oral precision therapy that selectively inhibits RET-altered cancers – – Genentech and Blueprint Medicines will co-commercialize Gavreto in the United States – – FDA also granted Priority Review to Gavreto for the treatment of people with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer – SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Genentech, a member
Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020
New data further reinforce Ocrevus (ocrelizumab) as a highly effective treatment option offering a favorable and consistent benefit:risk profile, with high treatment persistence and adherence
August has been a busy month for the U.S. Food and Drug Administration. The final two weeks are marked by a number of PDUFA dates, although a few of those drugs have already been approved.
Genentech and Regeneron Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Combination for COVID-19
REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection.